Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Product News News

VBLT – Announces top-line results from pivotal Phase 3 GLOBE study in patients with recurrent glioblastoma; study did not meet its pre-specified primary endpoint of overall survival.


Key Facts Surrounding This News Item


  • VBLT had a POWR Rating of C (Neutral) coming into today.
  • VBLT was 5.84% above its 10-Day Moving Average coming into today.
  • VBLT was 6.40% above its 20-Day Moving Average coming into today.
  • VBLT was -2.38% below its 50-Day Moving Average coming into today.
  • VBLT was -0.39% below its 100-Day Moving Average coming into today.
  • VBLT was 14.66% above its 200-Day Moving Average coming into today.
  • VBLT had returned -4.23% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Vascular Biogenics Ltd. – Ordinary Shares (VBLT)


Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel. View our full VBLT ticker page with ratings, news, and more.

VBLT at a Glance

VBLT Current POWR Rating™
Overall POWR Rating™
VBLT Current Price $1.13 3.42%
More VBLT Ratings, Data, and News

VBLT Price Reaction

The day of this event (Mar. 8, 2018)
VBLT Closing Price$2.65 61.03%
VBLT Volume7,897,700
4,107.18% from avg
Leading up to this event
VBLT 1-mo return7.94%
After this event
VBLT 1-day return161.54%
VBLT 3-day return180.41%
VBLT 5-day return186.32%

VBLT Price Chart


The Top Stocks For 2019

More Vascular Biogenics Ltd. - Ordinary Shares (VBLT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VBLT News
Page generated in 0.8945 seconds.